Clinical trial NCT05191862: Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers
Official title: An Open-Label, Randomized, Two-Treatment, Two-Sequence, Four-Period, Fully Replicated Crossover Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Intermittent Claudication
Keywords: Peripheral Artery Disease
Cilostazol
PMR
Extended-Release Tablet of Cilostazol
Lead sponsor: Genovate Biotechnology Co., Ltd.,
Sponsor class: INDUSTRY
First posted: 2022-01-14
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate-release tablet of cilostazol (Cilostazol) administered twice-daily in normal healthy male and female subjects under fasting conditions.


Eligibility criteria: Inclusion Criteria:

* Must be 18 to 45 years of age, inclusive, at screening.
* Absence of diseases that could affect the study outcomes.
* Having a body mass index (BMI) between 18.5 and 27.0, inclusive, at screening.
* Females must have a negative serum pregnancy test at screening.
* Understanding and willing to participate in the clinical study and able to comply with study procedures and visits.

Exclusion Criteria:

* History of bleeding tendency.
* Use of anticoagulant agent(s) within one (1) month prior to screening.
* Use of tobacco or nicotine products within six (6) months of screening.
* Intake of over the counter (OTC) or prescription drugs (other than hormonal contraceptives) within two (2) weeks prior to randomization.
* On any investigational drug(s) or therapeutic device(s) within thirty (30) days preceding screening; or anticipating use of any of these therapies during the course of the study (other than the study products).
* History of substance abuse, such as alcohol, IV drugs, and inhaled drugs, within one (1) year prior to screening.
* Known history of having Acquired Immunodeficiency Syndrome (AIDS) or positive pre-study result of infection with Human Immunodeficiency Virus (HIV); known history or positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within three (3) months of screening.
* Positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at any time during the study, either asymptomatic or present with symptoms of Coronavirus disease 2019 (COVID-19).
* Pregnant or breast feeding.
* Women of child-bearing potential not using an effective birth control method. Women of child-bearing potential are defined as women physiologically capable of becoming pregnant, UNLESS they meet the following criteria:

  1. Post-menopausal: 12 months of natural (spontaneous) amenorrhea or less than twelve (12) months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels \> 40IU/L, OR;
  2. Six (6) weeks post-surgical bilateral oophorectomy with or without hysterectomy, OR;
  3. Are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g. bilateral tubal ligation, hysterectomy), hormonal contraception (e.g. implantable, injectable, vaginal, patch, and oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for seven (7) days after study discontinuation.
* Known or suspected hypersensitivity to any ingredient of the study drug(s).
* Donated blood or lost more than 150 mL of blood within three (3) months prior to randomization or plans to donate blood or plasma within four (4) weeks after completion of the study.

Primary outcomes:
measure: Area under the curve, from time zero to last measureable time point (AUC 0-t )
timeFrame: 0-72 hours after morning dose
measure: AUC from time zero to infinity (AUC 0-∞)
timeFrame: 0-72 hours after morning dose
Secondary outcomes:
Other outcomes:
Locations:
city: Springfield
country: United States
facility: Bio-Kinetic Clinical Applications, LLC
state: Missouri
Study officials:
References: